Heart Failure, SystolicITISHOPE4HFNCT03183323
Implementation of Telerehabilitation In Support of HOme-based Physical Exercise for Heart Failure
A study testing Telerehabilitation in people with Heart Failure, Systolic and Heart Failure, Diastolic, run by Helse Nord-Trøndelag HF at 1 site in Norway.
Trial summary
ITISHOPE4HF is a randomized controlled trial of telerehabilitation in a heart failure population. The goal is to evaluate if a home-based telerehabilitation project can increase physical activity in heart failure patients. Patients will be provided telerehabilitation or advice on physical activity (standard care). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Heart Failure, Systolic, Heart Failure, Diastolic, Chronic Kidney Diseases
- What is being tested?
- Telerehabilitation
- Type of treatment
- Pill or oral medicine, Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 61 participants
- Where
- 1 siteNorway
- Study dates
- 8 Jun 2017to 28 Feb 2021
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Heart failure (HFpEF or HFrEF) according to European guidelines.
- Moderate or severe signs and symptoms of heart failure (NYHA II-III) in the 6 months prior to enrolment.
- N-terminal pro brain natriuretic peptide (NT-proBNP) > 300 pmol/L.
- Stable (> 4 weeks) medical therapy for risk factor control.
- Capability to provide signed, informed, written consent.
Who cannot join
- Attendance at a rehabilitation program in the 6 months prior to enrolment.
- Non-heart failure causes of heart failure symptoms (significant valvular disease, coronary disease available for revascularization, uncontrolled hypertension, arrhythmia).
- severe or very severe pulmonary disease (eg. COPD GOLD III-IV).
- presence of conditions which might prevent patients from safely exercising at home.
Trial locations and contacts
1 site in 1 country.
About this study
ITISHOPE4HF is a randomized controlled trial of telerehabilitation in a heart failure population. The goal is to evaluate if a home-based telerehabilitation project can increase physical activity in heart failure patients. Patients will be provided telerehabilitation or advice on physical activity (standard care).
Read the detailed description
Outpatient cardiac rehabilitation programs are well documented as an important part of treatment and care for heart failure patients. Training with instruction gives the participant a commitment to participate. The result is increased activity compared to controls.
This trial will include participants from the about 75 % of heart failure patients who for some reason do not participate in regular outpatient rehabilitation. Distance to rehabilitation centers and the psychological burden of a group setting are believed to be important reasons for not participating. Telerehabilitation can hopefully overcome these hurdles for many patients, and thereby provide instructed training for these patients.
The trial will also include patients with renal disease. Heart disease is the main cause of death in patients with renal disease, even at younger ages. Because of the complexity of both optimal medical treatment and fluid balance, these patients are often not included in clinical trials. The cardiorenal crosstalk will be explored, how in influence the heart failure phenotypes and the response to exercise.
- Conditions
- Heart Failure, Systolic, Heart Failure, Diastolic, Chronic Kidney Diseases, Cardiorenal Syndrome
- Being tested
- Telerehabilitation
- Keywords
- hfpef, hfref, cardiorenal syndrome, exercise, telerehabilitation, rehabilitation
- Medical subject headings
- Heart Failure, Systolic, Heart Failure, Diastolic, Renal Insufficiency, Chronic, Cardio-Renal Syndrome, Motor Activity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
TelerehabilitationBehavioural
Also called Mio Slice, Actigraph
Activity trackers. Mio Slice is worn through the whole study. Actigraph is worn for one week, at 4 different timepoints through the study.
| Study group | Role | What they receive |
|---|---|---|
| Telerehabilitation | Experimental | In addition to optimal medical treatment: 3 months of twice weekly group-based telerehabilitation through a video-conferencing on a tablet platform. In addition access to instruction videos for further self-training through the same platform and throughout the whole 2-year period. Electronic devices to trace activity. Receives: Behavioral: Telerehabilitation |
| Standard care | No intervention | In addition to optimal medical treatment: Advice on physical activity. Electronic devices to trace activity. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Improvement in long-term physical activity.
Change in physical activity between intervention and control group measured throughout the study with Actigraph activity trackers from baseline to 2 years.
Measured: 2 years
Secondary outcomes (8)
Changes in cardiac structure and function.
Echocardiographic indices - improvements from exercise.
Measured: 2 years.
Change in physical fitness.
The change in physical fitness at from baseline to 2 years follow-up.
Measured: 2 years
Effects on renal function.
Changes in renal function (GFR/proteinuria) by exercise.
Measured: 2 years.
Long-term effects on cardiovascular risk factors.
Blood measurements of Cardiac risk factors.
Measured: 2 years.
Effects on endothelial function.
Changes in peripheral arteries measured by vascular ultrasound from baseline to two years follow-up..
Measured: 2 years.
Change in long-term quality of life.
Measured via validated questionnaires at different point during follow-up.
Measured: 2 years.
Mid-term morbidity
Evaluate morbidity as hospitalization of cardiovascular causes
Measured: 2 years
Mid-term mortality
Mortality during follow-up
Measured: 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Jun 2017
- Study start8 Jun 2017
- Primary completion28 Feb 2021
- Study completion28 Feb 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Heart Failure, SystolicStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- RCT, 1:1 into telerehabilitation or standard care. Patients will be stratified by EF \>/\< 40 %, age \>/\< 60 years and by sex.
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 61 participants (actual)
Sponsor and investigators
- Lead sponsor
- Helse Nord-Trøndelag HF
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Havard Dalen, MD, PhD, Principal investigator, Norwegian University of Science and Tehnology
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03183323
- Sponsor's protocol ID
- LH2017_HOPE4HF
- Acronym
- ITISHOPE4HF
- Status last verified
- Apr 2022
- First submitted
- 30 May 2017
- Last updated
- 14 Apr 2022
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: Will follow the regulations and policy decided by the Norwegian University of Science and Technology
Publications
Lundgren KM, Langlo KAR, Salvesen O, Aspvik NP, Mo R, Ellingsen O, Vesterbekkmo E, Zanaboni P, Dalen H, Aksetoy IA. Exercise-Based Telerehabilitation for Heart Failure Patients Declining Outpatient Rehabilitation-A Randomized Controlled Trial. Med Sci Sports Exerc. 2025 Mar 1;57(3):449-460. doi: 10.1249/MSS.0000000000003590. Epub 2024 Nov 6.
PubMed 39501477Lundgren KM, Langlo KAR, Salvesen O, Zanaboni P, Cittanti E, Mo R, Ellingsen O, Dalen H, Aksetoy IA. Feasibility of telerehabilitation for heart failure patients inaccessible for outpatient rehabilitation. ESC Heart Fail. 2023 Aug;10(4):2406-2417. doi: 10.1002/ehf2.14405. Epub 2023 May 23.
PubMed 37221704
Study at a glance
From the registry record, last updated by the sponsor on 14 Apr 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Implementation of Telerehabilitation In Support of HOme-based Physical Exercise for Heart Failure
- ClinicalTrials.gov ID
- NCT03183323
- Acronym / sponsor ID
- ITISHOPE4HF / LH2017_HOPE4HF
- Conditions
- Heart Failure, Systolic, Heart Failure, Diastolic, Chronic Kidney Diseases, Cardiorenal Syndrome
- Keywords
- hfpef, hfref, cardiorenal syndrome, exercise, telerehabilitation, rehabilitation
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 61 participants (actual)
- Lead sponsor
- Helse Nord-Trøndelag HFUniversity, hospital or other
- Collaborators
- Norwegian University of Science and Technology, St. Olavs Hospital
- Study start
- 8 Jun 2017 (actual)
- Primary completion
- 28 Feb 2021 (actual)
- Study completion
- 28 Feb 2021 (actual)
- First posted
- 12 Jun 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
ITISHOPE4HF is a randomized controlled trial of telerehabilitation in a heart failure population. The goal is to evaluate if a home-based telerehabilitation project can increase physical activity in heart failure patients. Patients will be provided telerehabilitation or advice on physical activity (standard care).
Detailed description
Outpatient cardiac rehabilitation programs are well documented as an important part of treatment and care for heart failure patients. Training with instruction gives the participant a commitment to participate. The result is increased activity compared to controls.
This trial will include participants from the about 75 % of heart failure patients who for some reason do not participate in regular outpatient rehabilitation. Distance to rehabilitation centers and the psychological burden of a group setting are believed to be important reasons for not participating. Telerehabilitation can hopefully overcome these hurdles for many patients, and thereby provide instructed training for these patients.
The trial will also include patients with renal disease. Heart disease is the main cause of death in patients with renal disease, even at younger ages. Because of the complexity of both optimal medical treatment and fluid balance, these patients are often not included in clinical trials. The cardiorenal crosstalk will be explored, how in influence the heart failure phenotypes and the response to exercise.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
- Model description
- RCT, 1:1 into telerehabilitation or standard care. Patients will be stratified by EF >/< 40 %, age >/< 60 years and by sex.
| Arm | Type | Receives |
|---|---|---|
| Telerehabilitation | Experimental | Behavioral: TelerehabilitationIn addition to optimal medical treatment: 3 months of twice weekly group-based telerehabilitation through a video-conferencing on a tablet platform. In addition access to instruction videos for further self-training through the same platform and throughout the whole 2-year period. Electronic devices to trace activity. |
| Standard care | No intervention | –In addition to optimal medical treatment: Advice on physical activity. Electronic devices to trace activity. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Heart failure (HFpEF or HFrEF) according to European guidelines.
- Moderate or severe signs and symptoms of heart failure (NYHA II-III) in the 6 months prior to enrolment.
- N-terminal pro brain natriuretic peptide (NT-proBNP) > 300 pmol/L.
- Stable (> 4 weeks) medical therapy for risk factor control.
- Capability to provide signed, informed, written consent.
Key exclusion criteria (4 listed)
- Attendance at a rehabilitation program in the 6 months prior to enrolment.
- Non-heart failure causes of heart failure symptoms (significant valvular disease, coronary disease available for revascularization, uncontrolled hypertension, arrhythmia).
- severe or very severe pulmonary disease (eg. COPD GOLD III-IV).
- presence of conditions which might prevent patients from safely exercising at home.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| TelerehabilitationAlso: Mio Slice, ActigraphActivity trackers. Mio Slice is worn through the whole study. Actigraph is worn for one week, at 4 different timepoints through the study. | Behavioural | Telerehabilitation |
Primary outcome
Improvement in long-term physical activity.
Time frame: 2 years
Change in physical activity between intervention and control group measured throughout the study with Actigraph activity trackers from baseline to 2 years.
8 secondary outcomes
Changes in cardiac structure and function.
Time frame: 2 years.
Change in physical fitness.
Time frame: 2 years
Effects on renal function.
Time frame: 2 years.
Long-term effects on cardiovascular risk factors.
Time frame: 2 years.
Effects on endothelial function.
Time frame: 2 years.
Change in long-term quality of life.
Time frame: 2 years.
Mid-term morbidity
Time frame: 2 years
Mid-term mortality
Time frame: 2 years
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Apr 2022.
- Derived from this study: PubMed 39501477Lundgren KM, Langlo KAR, Salvesen O, Aspvik NP, Mo R, Ellingsen O, Vesterbekkmo E, Zanaboni P, Dalen H, Aksetoy IA. Exercise-Based Telerehabilitation for Heart Failure Patients Declining Outpatient Rehabilitation-A Randomized Controlled Trial. Med Sci Sports Exerc. 2025 Mar 1;57(3):449-460. doi: 10.1249/MSS.0000000000003590. Epub 2024 Nov 6.
- Derived from this study: PubMed 37221704Lundgren KM, Langlo KAR, Salvesen O, Zanaboni P, Cittanti E, Mo R, Ellingsen O, Dalen H, Aksetoy IA. Feasibility of telerehabilitation for heart failure patients inaccessible for outpatient rehabilitation. ESC Heart Fail. 2023 Aug;10(4):2406-2417. doi: 10.1002/ehf2.14405. Epub 2023 May 23.
- Individual participant dataSharing planned: Undecided. Will follow the regulations and policy decided by the Norwegian University of Science and Technology
Related trials for Heart Failure, Systolic
Not yet recruiting
RELIEVE-HFrEF TRIAL: REducing Lung congestIon Symptoms Using the v-wavE Shunt in adVancEd Heart Failure With Reduced EF
Heart Failure and Reduced Ejection Fraction, Heart Failure Chronic
RecruitingPhase 1
A Study of LY3971297 in Participants With Heart Failure
Heart Failure, Heart Failure, Diastolic
RecruitingPhase 2/3
Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)
Heart Failure, Left Ventricular Systolic Dysfunction
RecruitingPhase 3
A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction
Left Ventricular Systolic Dysfunction, Heart Failure (Pediatric)
RecruitingPhase 1/2
Endocardial Delivery for Myocardial Regeneration Using Allogeneic iPSC-derived Cardiomyocyte Spheroids for HF With Systolic Dysfunction (EMERALD Study)
Heart Failure, Ischemic Heart Failure
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Havard Dalen, MD, PhD principal investigator
Norwegian University of Science and Tehnology
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Telerehabilitation in people with Heart Failure, Systolic and Heart Failure, Diastolic, run by Helse Nord-Trøndelag HF at 1 site in Norway.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 14 Apr 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Norway. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Improvement in long-term physical activity. (time frame: 2 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03183323, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Apr 2022.